{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:42:02Z","timestamp":1777934522855,"version":"3.51.4"},"reference-count":13,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T00:00:00Z","timestamp":1634515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The addition of imatinib to the therapeutic arsenal for chronic myeloid leukaemia (CML) has changed the natural course of the disease, in such a way that it is now considered a chronic pathology. However, to achieve therapeutic success, it is necessary to reach adequate plasma concentrations to ensure efficacy and safety. In this study, we aimed to evaluate the plasma concentration of imatinib, analysing its influence on effectiveness and safety in patients with CML.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a descriptive, multicentre study in which imatinib plasma levels from patients diagnosed with CML between 2019\u20132020 were analysed. An optimal therapeutic range of 750\u20131500\u2009ng\/mL was established for the stratification of patients, according to their minimum plasma concentrations measured at steady state (Cssmin).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 28 patients were included, of whom only 39.3% (n\u2009=\u200911) showed Cssmin within the therapeutic range. 100% of patients with Cssmin &gt;750\u2009ng\/mL achieved an optimal molecular response, while only 50% of patients with Cssmin &lt;750\u2009ng\/mL achieved an optimal molecular response ( p\u2009=\u20090.0004). The toxicity rate was 36.4% for patients with Cssmin &gt;1500\u2009ng\/mL and 5.9% for those with Cssmin &lt;1500\u2009ng\/mL ( p\u2009=\u20090.039).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study aimed to describe the correlation between the toxicity and effectiveness of imatinib according to its Cssmin in routine clinical practice conditions. Based on our findings, it would be certainly justified to monitor patient plasma concentrations of imatinib on a daily routine basis in our hospitals.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552211052535","type":"journal-article","created":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T02:23:07Z","timestamp":1634610187000},"page":"40-44","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Imatinib plasma levels in patients with chronic myeloid leukaemia under routine clinical practice conditions"],"prefix":"10.1177","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7786-980X","authenticated-orcid":false,"given":"Betel","family":"Del Rosario Garc\u00eda","sequence":"first","affiliation":[{"name":"Servicio de Farmacia, Complejo Hospitalario Universitario de Canarias, Tenerife, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iris","family":"Gonz\u00e1lez Garc\u00eda","sequence":"additional","affiliation":[{"name":"Servicio de Farmacia, Hospital Universitario Nuestra Se\u00f1ora De La Candelaria, Tenerife, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Micaela","family":"Vi\u00f1a Romero","sequence":"additional","affiliation":[{"name":"Servicio de Farmacia, Hospital Universitario Nuestra Se\u00f1ora De La Candelaria, Tenerife, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7598-3732","authenticated-orcid":false,"given":"Jonathan","family":"Gonz\u00e1lez Garc\u00eda","sequence":"additional","affiliation":[{"name":"Servicio de Farmacia, Complejo Hospitalario Universitario de Canarias, Tenerife, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8202-4855","authenticated-orcid":false,"given":"Ruth","family":"Ramos D\u00edaz","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3n Canaria para la Investigaci\u00f3n Sanitaria (FUNCANIS), Tenerife, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6195-0646","authenticated-orcid":false,"given":"Ivette","family":"Mourani Padr\u00f3n","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3n Canaria para la Investigaci\u00f3n Sanitaria (FUNCANIS), Tenerife, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunil","family":"Lakhwani Lakhwani","sequence":"additional","affiliation":[{"name":"Servicio de Hematolog\u00eda, Complejo Hospitalario Universitario de Canarias, Tenerife, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gloria Julia","family":"Nazco Casariego","sequence":"additional","affiliation":[{"name":"Servicio de Farmacia, Complejo Hospitalario Universitario de Canarias, Tenerife, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Guti\u00e9rrez Nicol\u00e1s","sequence":"additional","affiliation":[{"name":"Servicio de Farmacia, Complejo Hospitalario Universitario de Canarias, Tenerife, Spain"},{"name":"Unidad de Investigaci\u00f3n del Complejo Hospitalario Universitario de Canarias, Tenerife, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2021,10,18]]},"reference":[{"key":"bibr1-10781552211052535","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25011"},{"key":"bibr2-10781552211052535","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6600591"},{"key":"bibr3-10781552211052535","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.8154"},{"key":"bibr4-10781552211052535","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116475"},{"key":"bibr5-10781552211052535","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-036012"},{"key":"bibr6-10781552211052535","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e3181b2c8cf"},{"key":"bibr7-10781552211052535","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-501569"},{"key":"bibr8-10781552211052535","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.133.133"},{"key":"bibr9-10781552211052535","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.045666"},{"key":"bibr10-10781552211052535","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2014.04.015"},{"key":"bibr11-10781552211052535","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-015-2849-x"},{"key":"bibr12-10781552211052535","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.787"},{"key":"bibr13-10781552211052535","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000654"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552211052535","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552211052535","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552211052535","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:25:38Z","timestamp":1777688738000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552211052535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,18]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.1177\/10781552211052535"],"URL":"https:\/\/doi.org\/10.1177\/10781552211052535","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,18]]}}}